Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma

NCT03112174 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.

NCT NCT03112174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03112174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma
Lead sponsor
Pharmacyclics LLC.
Phase
Phase 3
Overall status
Completed
Start date
June 19, 2017
Completion date
June 27, 2024
Enrollment
366 (actual)
Sites
120

Conditions

As the registry lists them; a condition with its own page is linked.

mantle-cell lymphoma